News & Updates

Taking aspirin in the adjuvant setting does not appear to lower the risk of recurrence or improve survival in patients with high-risk nonmetastatic breast cancer, as shown in the results of the phase III Alliance A011502 trial.

Sexual disorders are common among breast cancer patients, and such problems may continue for up to 2 years after the cancer diagnosis, according to a study. Notably, a communication gap regarding sexuality persists between patients and healthcare providers.

In the second interim analysis of part 1 of the phase III ENGOT-EN6-NSGO/GOG-3031/RUBY trial, dostarlimab plus carboplatin/paclitaxel (CP) chemotherapy delivered a significant survival benefit in women with primary advanced or recurrent endometrial cancer.

Expansion of a territory-wide cervical screening programme to train a group of local South Asian women has enabled education regarding cervical cancer and screening services among their peers, and considerably improved screening uptake.

Following first-line (1L) brigatinib treatment, most patients with ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) received an ALK tyrosine kinase inhibitor (TKI) as second-line (2L) therapy and experienced prolonged clinical benefit, a retrospective chart review of patients enrolled in the phase III ALTA-1L trial has shown.